Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients-Reference-Cited by-同舟云学术

Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients

Published:2023 Issue:1 Volume:19 Page:1
ISSN:2752-5481
Container-title:Oncology & Haematology
language:en
Short-container-title:

Author:

Lucas Tylan,Chan Joshua,Chopra Neha, , ,

Abstract

Metastatic hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) breast cancer survival outcomes have improved significantly; however, once endocrine resistance develops, response rates to systemic treatments are limited. Within the developing field of antibody–drug conjugates, the TROPiCS-02 study showed a significant improvement in progression-free survival with sacituzumab govitecan compared with physician’s choice of chemotherapy in patients with endocrine-resistant, metastatic, HR+/HER2- breast cancer. Additionally, overall survival similarly improved (14.4 months versus 11.2 months, respectively). We discuss the role of sacituzumab govitecan and its role in practice, looking at the direct impact it has in metastatic HR+/HER2- breast cancer.

Funder

This article is published under the Creative Commons Attribution Non-commercial License.

Publisher

Touch Medical Media, Ltd.

Reference42 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–717. DOI: 10.1016/S0140-6736(05)66544-0.

2. BEER. Female breast cancer subtypes – Cancer STAT facts. Available at: https://seer.cancer.gov/statfacts/html/breast-subtypes.html (Date last accessed: 6 December 2022).

3. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106:dju055. DOI: 10.1093/jnci/dju055.

4. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107:djv048. DOI: 10.1093/jnci/djv048.

5. Matutino A, Joy AA, Brezden-Masley C, et al. Hormone receptor–positive, HER2-negative metastatic breast cancer: Redrawing the lines. Curr Oncol. 2018;25:S131–41. DOI: 10.3747/co.25.4000.